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The proliferation of commercially-available
"kits" for the clinical laboratory has resulted in such
a technological surfeit that one or more kits are
available for virtually every type of commonly performed test. Such kits offer prepackaged convenience
and, under some circumstances, economies in the
laboratory. A few offer technical procedures which
are superior to standard methods.
In spite of their apparent simplicity, commercial
availability of a reagent kit does not provide any assurance that it will perform satisfactorily or that the
resulting data will be accurate. In contrast to therapeutic agents, federal regulation of the manufacture
of diagnostic kits has only recently been instituted,
and it remains for the user to determine whether a
particular kit does in fact meet the specifications
stated in promotional material. The selection and the
continuing evaluation of diagnostic kits present problems to every laboratory, whether the laboratory is
in the physician's office or in a large hospital.
Perhaps the simplest type of kit is a prepared
reagent for a certain determination. This category
would include specific antisera for blood grouping or
other purposes, as well as standard chemical reagents. Usually, however, the word "kit" is used to
describe a prepackaged set of multiple reagents for
carrying out a certain test in the laboratory. Many
such multiple-reagent kits are based upon standard,
accepted methods; those from reliable manufacturers
offer the advantages of standard methodology and
elimination of reagent preparation. Some kits are
based upon manufacturer-developed methods which
are usually patented or kept as proprietary secrets.
Some of these manufacturer-developed methods are
acceptable; some, no doubt, have been developed
primarily to permit a wider profit margin. Lastly,
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several well-known firms are marketing kits which
are suitable only for their own analytical instruments. This presents a double dilemma for the purchaser, since it is necessary not only to evaluate the
kit but the instrument as well.
Selection of Kits. Most physicians are deluged
with flyers and advertisements which suggest that the
purchase of a few kits is an efficient and entirely
satisfactory method of installing an instant clinical
laboratory. These blandishments frequently lead to an
illogical and expensive system for providing laboratory data. The first question to be asked is not which
kits to buy but rather which determinations should
be done in the laboratory. If a test is definitely
needed, purchase of a kit is one of the alternative
methods for making it available. Particularly in the
physician's office, the convenience, the elimination
of reagent preparation and savings in personnel time
are advantageous. Use of a kit usually results in a
higher per-test cost than having the test done in a
large, automated laboratory, but the advantages of
using kits sometimes outweigh these higher costs.
Kits from different manufacturers will offer different
analytical methods, differing numbers of tests per kit,
different instrument requirements and, of course, different prices.
An important principle in selecting any type of
laboratory kit is to require the manufacturer to provide relevant experimental data which substantiate
any claims regarding performance of the kit. Descriptions such as accurate, precise, simple, inexpensive
and reliable are all relative. Unless the manufacturer
can produce data, preferably substantiated by an independent investigator, regarding these parameters
of performance, further consideration of using the
kit should not be entertained. Most reputable manufacturers will supply reprints of articles describing
such evaluations.
Evaluation of Kits. If a laboratory is to produce
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reliable data, a critical evaluation of each method
must be carried out prior to its introduction as a
routine procedure. It is immaterial whether or not
the procedure utilizes a prepackaged kit. Such an
evaluation should make full use of any data collected
by other laboratories, but an experimental evaluation
by the laboratory which is to use the kit is essential.
Although kits come in various forms, there are
two major categories of laboratory tests for which
they will be used-qualitative tests and quantitative
tests. Qualitative tests are those for which the results
can be expressed as a yes or no, positive or negative
or present or absent report. Pregnancy tests and tests
for urinary glucose are examples of qualitative tests.
Quantitative tests are those which are used for measurement of a specific constituent and results are
expressed in numerical terms. The evaluation of a
kit will differ depending on whether it is used for a
qualitative or quantitative procedure.
Comparison with Reference Method. Evaluation, no matter what is being evaluated, is a comparative process. If a kit merely supplies reagents
necessary to do a standard laboratory test, data on
the standard test are readily available in published
form. More often, the kit will be a modification of a
standard method or, occasionally, a new approach
to measuring the same constituent. In either situation, the manufacturer should provide experimental
data which compare the kit procedure to an accepted, established method.
For quantitative tests, the parameters which
should be examined are accuracy, precision and
range of linearity over which measurements can be
made. Accuracy is an elusive parameter to evaluate,
and a comparison of results using the kit with those
obtained by a standard method is acceptable. Precision can be evaluated by replicate determinations
and linearity by measuring a series of samples with
varying concentrations of the constituent being measured. An excellent example of such a comparison
is the study by Barnett, Cash and Junghans (2) in
which cholesterol measurements using 12 different
kits were compared to those using the Abell-Kendall
method. They concluded that only two of the 12
kits being marketed at the time of the study were
acceptable for clinical use . Other published evaluations should be equally disconcerting to any laboratory which uses a kit without first subjecting it to
rigorous performance trials. Kim, Waddell and
Logan ( 6) measured sodium and potassium with
chemical kits manufactured by the Stanbio Laborn-
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tory, San Antonio, Texas and by Medi-Chem, Santa
Monica, California. Results were compared with
those obtained by standard flame photometric techniques, and the authors concluded that both kits
gave "diagnostically unsatisfactory results." A study
by Dietz, Rubenstein and Lubrano (5) which involved serum cholinesterase measurements using the
Acholest® kit manufactured by E. Fougera and Co.,
Hicksville, New York, provides a shocking indictment of the lax standards set by some commercial
firms. The Acholest® method "failed to detect 12 of
20 cases at high risk of prolonged apnea after succinylcholine." Similar comparative studies of kits for
less complicated procedures such as glucose and urea
indicate that some are entirely suitable for these
measurements (7, 9, 11) . It is noteworthy that
Logan, Waddell and Krynski (9) found that the
kits which were the most expensive and which revealed the least information concerning their constitution gave the poorest performances.
The evaluation of comparative data for qualitative tests frequently is more difficult than for quantitative tests. The two parameters corresponding to
accuracy and precision are validity and reproducibility. Reproducibility can be studied through replicate tests on the same group of samples; validity,
however, like accuracy, may have to be evaluated
by comparison with a reference method. The objective for all qualitative tests is a positive result when
the constituent or disease is present and a negative
result when it is not. For example, serological tests
for syphilis are usually compared to the fluorescent
treponemal antibody-absorbed (FTA-ABS) test.
Since the serological test is used primarily as a
screening procedure, acceptable performance would
result in no false negatives and as few false positives
as possible. Frequently, the evaluation must include
consideration of the clinical context in which the
test will be used. Tests for pregnancy are usually
evaluated by testing large numbers of pregnant and
nonpregnant women. A test which gave positive
results in 97 % of women in the second trimester
of pregnancy clearly would not be as useful as one
which gave similar accuracy during the first three
weeks. The undesirability of false positive pregnancy
tests is readily apparent.
In addition to comparisons with reference
methods, information provided by the manufacturer
should include predisposing test conditions or patient abnormalities which will affect the test and give
inaccurate or undependable results. Such interfering
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conditions are particularly troublesome with newly
developed tests such as radioimmunoassays. Tests for
digoxin, for example, may measure not only digoxin
but also its metabolites ( 10) . More worrisome, however, are reports that therapeutically administered
compounds such as cortisol and spironolactone may
react with the digoxin-binding antibody to give erroneous results.
Laboratory Trials. Although few laboratories
will carry out an evaluation of a kit as elaborate
as those which are described in scientific journals, it
is falacious to assume that results similar to those in
published articles can be obtained automatically by
any kit purchaser. The procedures for experimental
evaluation may vary from kit to kit, but critical
testing of every type of kit by the laboratory in which
it is to be used is essential.
Meticulous examination of the instructions
which accompany the kit will frequently eliminate
unnecessary work. The instructions should present
a logical and detailed outline of each step in the
procedure, with a clear indication of where errors
might occur, what types of instruments are suitable,
in which steps timing is critical and how results are
to be calculated from instrument readings. The instructions should be followed compulsively under all
circumstances. Suitable standards should be included
with aJI kits for quantitative measurements and the
standards should have concentrations which span the
range of clinically useful measurements. Controls
should be run with each batch of any procedure,
whether it is a quantitative or a qualitative one and,
if possible, control solutions should be obtained from
a manufacturer other than the supplier of the kit.
Qualitative tests generally should have both a positive
and a negative control; these usually accompany the
kit, however, since they may be the only suitable
controls available.
Replicate determinations on different days of
one, or preferably several, control solutions provides
an indication of the precision which might be expected. If reproducibility is unsatisfactory, the problem may reside either in the kit or in the technique.
If errors can be traced to faulty technique which is
corrected, the experiments should be repeated ; if not,
the kit should not be accepted for routine use in the
laboratory. A second useful step in evaluating a kit
is separation of patient samples into two aliquots,
one to be run by the kit method and the other to be
submitted to a reference laboratory. A minimum of
a dozen, and preferably several times that number,

CONN : PREPACKAGED KITS

split samples should be analyzed before acceptance
of the kit for routine use. Many manufacturers will
supply free samples of kits for preliminary evaluation; this practice, however, should have no influence
on the laboratory in regard to which kits are tested
and which are finally selected for routine use.
Evaluation of an instrument which is designed
for use with kits for a variety of procedures may be
quite time-consuming, since each procedure for
which a kit is available must be evaluated separately.
Logan and Sunderland ( 8) evaluated the Unitest
System® marketed by Bio-Dynamics, Inc., Indianapolis, Indiana, and Diagnotest® marketed by
Dow Chemical Company, Diagnostic Products Division, Indianapolis, Indiana. For each instrument,
some of the kits performed unsatisfactorily, and the
authors concluded that personnel without technical
training could not obtain reliable data with either
system.
Continuing Evaluation. Initial evaluation and
acceptance of a kit for routine use in the laboratory
does not assure continuing satisfactory performance.
Most important, the use of kits does not obviate
the need for strict quality control measures. Suitable
quality control solutions should be run with each
batch of procedures, strict limits for variation of the
control solution should be set and all data should
be rejected if control readings are out of the predetermined range. Lot numbers of each reagent or
kit should be entered into the laboratory log book
and when a new lot number is used, samples should
be run in duplicate with the old and the new reagents
to permit comparison between lots.
FDA Regulations Regarding Kits. It perhaps
should be stressed that most of the laboratory kits
on the market today were developed during a period
when there were no federal regulations setting minimum performance standards. As early as 1966 the
American Association of Clinical Chemists (1) published policies regarding reagent sets and kits which,
had they been followed by all manufacturers, might
have greatly reduced the number of subsequent
articles devoted to documenting the inadequacies of
many kits. Manufacturers also could voluntarily
submit kits to the College of American Pathologists
for evaluation; however, compliance with the recommendations of the college in the case of inadequate
kits was also voluntary. Published evaluations of all
types of kits clearly indicate that some are unsatisfactory, some are satisfactory and some are outstanding in meeting performance standards.
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In January 1972, the Food and Drug Administration announced that existing legislation gave them
authority to exercise regulatory control over diagnostic kits to ensure that they deliver a consistently
high level of quality and performance (3). A statement of procedures for developing policy and interpretive regulations was published in August 1972
(4). Briefly, these regulations require that diagnostic
kits be accurate and reliable, that manufacturers test
and evaluate kits prior to marketing them and verify
results against a generally accepted procedure, that
premarket testing is done to find if predisposing
patient abnormalities will affect the test and that the
labeling of all kits contains adequate directions for
use. The labeling directions must include complete
information on accuracy, reproducibility and sensitivity performance. The FDA intends to establish
standards of performance for each type of laboratory
kit and require manufacturers to meet these standards. Establishing pertinent standards will be time
consuming (the FDA intends to start with glucose
and hemoglobin), but merely requiring manufacturers to provide evidence that kits will perform as
claimed will be helpful for anyone who must decide
which kit to purchase. The FDA is already enforcing these regulations and has required two manufacturers of pregnancy test kits to recall their products.
Cost Evaluation. The cost of performing laboratory tests is causing increasing concern because of
the dramatic increase in the use of laboratory data in
patient care and because many of the newer tests are
more complicated and thus more expensive. Evaluation of a laboratory procedure should include the
cost of doing it. In a physician's office or a small
laboratory, such cost accounting can be quite simple,
since it is easy to calculate the cost per test done by
a kit method and to measure personnel time involved. Since most kits have expiration dates, the
cost per test of the kit should take into account the
necessity for discarding outdated reagents. Generally
speaking the cost of a quantitative measurement
carried out by a kit method will be considerably
higher than the same test carried out on automated
laboratory instruments. On the other hand, even
large laboratories use prepared reagents and kits for
performing some of the simpler tests and these tests
can be performed in the office laboratory at the same
or perhaps lower cost than in a large laboratory.
Higher costs for performing tests in physicians' offices may be offset by convenience to the patient or
the necessity for having data immediately available.
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Summary. Prepackaged laboratory kits for performing diagnostic procedures are frequently the
most suitable alternative in the selection of laboratory methods, especially in physicians' offices and
small laboratories. Because of the previous lack of
governmental regulations covering the manufacture
of kits, many kits now on the market do not perform
adequately and may produce misleading results.
Each laboratory must evaluate each type of kit
before it is put into routine use. This evaluation
should include a review of published experimental
data, comparison of results using the kit to results
using a reference method and an experimental
evaluation of the kit in the laboratory in which it is
to be used.
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